Groundbreaking Parkinson’s trial publishes results

News

Author: Simge Eva DoganPublished: 7 March 2019

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Parkinson's trial

A breakthrough Parkinson’s trial that featured in a two-part documentary on UK television channel BBC Two has published its results.

The study, which featured in the documentary ‘The Parkinson’s Drug Trial: A miracle cure?’, aimed to investigate whether it was possible to restore damaged neurons by administering protein Glial Cell Line Derived Neurotrophic Factor (GDNF).

As part of the trial, scientists initially infused GDNF into the brains of six participants living with the condition. Researchers then invited a further 35 individuals with Parkinson’s to take part, with approximately half being administered with a placebo infusion.

Although not conclusive, the results suggest that GDNF had an impact on the brain and researchers believe the topic is worthy of further study.

Dr Alan Whone, principal investigator on the trial, said: “This represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells that are gradually destroyed in Parkinson’s.

To read more on this topic click here.

For more information on the latest Parkinson’s research please visit the EPDA website.


Read more:

Course for Parkinson’s nurses launches in Slovenia

Could treadmill training improve Parkinson’s symptoms?

Go Back

Share this story

Comments


Related articles


PL_stir-fried-broccoli_2

Recipes & Nutrition

Colourful broccoli, shiitake mushrooms and cashew nut stir-fry

A quick stir-fry that’s both easy to make and nutritious

READ MORE
Maryum Ali with her father Muhammed Ali

Global update

10 of our favourite Parkinson’s Life stories from 2021

What has been your favourite article about Parkinson’s disease?

READ MORE
John McLean at work

Perspectives

‘Which Way Up’: documentary following painter John McLean

UK screening of film about painter with Parkinson’s, John McLean

READ MORE